Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- cell therapy
- Stem cells
- Regenerative medicine
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28201
the technology is cardiac related.
IPSCIO Record ID: 3533
The patents relate to certain gene therapy applications of the membrane-bound form of the Stem Cell Factor gene (mSCF) for treatment of cardiac ischemia.
The Licensor intellectual property and research involves gene therapy technologies.
IPSCIO Record ID: 28172
The Licensee may assigning or subcontract the rights with permission from the Licensor.
2004-182 Derivation of a Cardiopoetic Cellular Phenotype from a Stem Cell Source.
And the related Patents and Patent Applications;
06/592,871 Stem Cells and treatment of Vascular Tissue
06/680,775 Treating Cardiovascular Tissue
06/832,845 Methods and Materials for providing Cardiac Cells
PCT/US2005/026800 Treating Cardiovascular Tissue
PCT/US2008/064895 Methods and Materials for using Cells to treat Heart Tissue
PCT/US2009/044714 Compositions and Methods for Using Cells to treat Heart Tissue
PCT/US2009/044751 Methods for determining the Cardio Generative Potential of Mammalian Cells
3. Paragraph 2.02 is replaced with the following;
Field of Use means treatment of embryonic and autologus mesenchymal stem cells to guide development into cardiomyocytes for the treatment of myocardial infarction, ischemic heart disease, ischemic and non-ischemic cardiomyopathy.
The Belgian biopharma company is involved in the discovery, development and commercialisation of regenerative and protective therapies for the treatment of cardiac diseases.
IPSCIO Record ID: 230517
The IP includes products and technologies like MyoCell for the treatment of heart damage. These are autologous muscle-derived cellular therapies designed to populate regions of scar tissue within a patientâ€™s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
MyoCell is an innovative clinical therapy designed to populate regions of scar tissue within a patientâ€™s heart with autologous muscle cells, or cells from a patientâ€™s body, for the purpose of improving cardiac function in chronic heart failure patients.